2016
Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control study
Kho PF, Fawcett J, Fritschi L, Risch H, Webb PM, Whiteman DC, Neale RE. Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control study. Cancer Causes & Control 2016, 27: 1457-1464. PMID: 27817122, DOI: 10.1007/s10552-016-0824-4.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsUse of NSAIDsPopulation-based case-control studyCase-control studyAnti-inflammatory drugsPancreatic cancerProtective effectHistory of NSAIDsUnconditional multivariable logistic regressionSelective COX-2 inhibitorsMultivariable logistic regressionPancreatic cancer riskSex-matched controlsCOX-2 inhibitorsPancreatic cancer studiesStatin useMedication useSmoking statusCancer riskMedication sectionStatinsCancerLogistic regressionMore frequent usersCancer studies
2006
The prostacyclin receptor induces human vascular smooth muscle cell differentiation via PKA
Fetalvero K, Shyu M, Nomikos A, Chiu Y, Wagner R, Powell R, Hwa J, Martin K. The prostacyclin receptor induces human vascular smooth muscle cell differentiation via PKA. The FASEB Journal 2006, 20: a665-a666. DOI: 10.1096/fasebj.20.4.a665-d.Peer-Reviewed Original ResearchVascular smooth muscle cellsHuman vascular smooth muscle cellsCardiovascular eventsHuman vascular smooth muscle cell differentiationProstacyclin receptorVSMC phenotypeSelective COX-2 inhibitorsAdverse cardiovascular eventsSuperficial femoral arteryProstacyclin analogue iloprostCOX-2 inhibitorsSmooth muscle cellsCAMP/PKA signalingVascular smooth muscle cell differentiationSmooth muscle differentiation markersSmooth muscle cell differentiationArterial injuryCardioprotective effectsFemoral arteryAnalogue iloprostClinical trialsH-caldesmonOrgan donorsAnimal modelsNM iloprost
2005
Expression of Mediators of Renal Injury in the Remnant Kidney of ROP Mice Is Attenuated by Cyclooxygenase-2 Inhibition
Cheng H, Zhang M, Moeckel GW, Zhao Y, Wang S, Qi Z, Breyer MD, Harris RC. Expression of Mediators of Renal Injury in the Remnant Kidney of ROP Mice Is Attenuated by Cyclooxygenase-2 Inhibition. Nephron 2005, 101: e75-e85. PMID: 15995341, DOI: 10.1159/000086645.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsConnective Tissue Growth FactorCyclooxygenase 2 InhibitorsFibronectinsGlomerulosclerosis, Focal SegmentalImmediate-Early ProteinsIntercellular Signaling Peptides and ProteinsKidneyKidney TubulesMiceMice, Inbred StrainsNephrectomyProteinuriaProto-Oncogene Proteins c-metPyrazolesSulfonamidesTissue DistributionConceptsCyclooxygenase-2 inhibitionROP miceSC58236 treatmentRenal injuryRemnant kidneyImmunoreactive COX-2Immunoreactive TGF-beta1Selective COX-2 inhibitorsSystemic blood pressureConnective tissue growth factorSubtotal renal ablationRenal tubulointerstitial injuryExpression of mediatorsCOX-2 inhibitorsTissue growth factorCollagen IV mRNATubulointerstitial injuryBlood pressureRenal ablationSignificant albuminuriaCOX-2Macrophage markersMouse modelTGF-beta1Remnant group
2002
Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension1
Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, Mckanna JA, Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension1. Kidney International 2002, 62: 929-939. PMID: 12164875, DOI: 10.1046/j.1523-1755.2002.00520.x.Peer-Reviewed Original ResearchConceptsCOX-2 expressionCOX-2 inhibitorsDiabetic groupRenal injuryDiabetic ratsImmunoreactive COX-2 expressionCortical thick ascending limbSelective COX-2 inhibitorsSystolic blood pressureModel of diabetesVascular endothelial growth factorDevelopment of glomerulosclerosisCOX-2 inhibitionThick ascending limbEndothelial growth factorMesangial sclerosis indexTubulointerstitial injuryDiabetic nephropathyBlood pressureChronic treatmentSubtotal nephrectomySclerosis indexBlood glucoseMacula densaRenal cortex
2001
NSAIDs and the Kidney Revisited: Are Selective Cyclooxygenase-2 Inhibitors Safe?
Eras J, Perazella M. NSAIDs and the Kidney Revisited: Are Selective Cyclooxygenase-2 Inhibitors Safe? The American Journal Of The Medical Sciences 2001, 321: 181-190. PMID: 11269794, DOI: 10.1097/00000441-200103000-00005.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsCOX-2 selective inhibitorsSelective cyclooxygenase-2 inhibitorRenal effectsCyclooxygenase-2 inhibitorNonselective nonsteroidal anti-inflammatory drugsSelective nonsteroidal anti-inflammatory drugsSelective COX-2 inhibitorsAdverse renal effectsBaseline patient characteristicsAdverse gastrointestinal effectsCOX-1/COXCyclooxygenase enzyme activityAnti-inflammatory drugsCOX-2 inhibitorsCOX-2 enzymePatient characteristicsGastrointestinal effectsChronic painGastric erosionsInflammatory conditionsClinical studiesClinical investigationKidney tissueKidney
2000
Are selective COX-2 inhibitors nephrotoxic?
Perazella M, Eras J. Are selective COX-2 inhibitors nephrotoxic? American Journal Of Kidney Diseases 2000, 35: 937-940. PMID: 10793030, DOI: 10.1016/s0272-6386(00)70266-6.Peer-Reviewed Original ResearchConceptsHigh-risk patientsRenal insufficiencySelective cyclooxygenase-2 enzyme inhibitorsSuch high-risk patientsNonsteroidal anti-inflammatory drugsSelective COX-2 inhibitorsChronic renal impairmentChronic renal insufficiencyAcute renal failureAcute renal insufficiencyAdverse gastrointestinal effectsCyclooxygenase-2 enzyme inhibitorsAnti-inflammatory drugsCourse of therapyCOX-2 inhibitorsPain syndromeRenal impairmentRenal failureGastrointestinal effectsNephrotoxic potentialInflammatory diseasesEnzyme inhibitorsPatientsInsufficiencyInhibitors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply